Inhibrx Biosciences Inc. (INBX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
11025 North Torrey Pines Road
La Jolla, CA 92037
United States of America (the)
Phone
858-795-4220
Website
Sector
Healthcare
Industry
Biotechnology
Employees
109
First IPO Date
May 29, 2024
| Name | Title | Pay | Year Born |
| Mark Paul Lappe | Founder, Chief Executive Officer & Chairman | 2.89M | 1967 |
| Kelly Devine Deck | Executive Vice President, Chief Financial Officer & Treasurer | 766,410 | 1980 |
| David Matly | President | 911,655 | 1986 |
| Carlos Bais | EVice President & Chief Scientific Officer | 0 | N/A |
| Josep Garcia | Executive Vice President & Chief Clinical Development Officer | 0 | N/A |
| Ashraf Amanullah | Executive Vice President & Chief Technical Operations Officer | 0 | 1968 |
| Bonne Adams | Vice President of Operations | 0 | 1977 |
| Leah Pollema | Vice President, General Counsel & Corporate Secretary | 0 | N/A |
| Kate Burke | Vice President of Accounting | 0 | N/A |
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.